GlassScriptPhysician profile
Sunil Sherchan
NPI 1962885350
$1,524.45
in general payments reported to CMS, 2019-2025
23 companies · $83.41 in 2025
The $83.41 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2021: $60.28 · 2022: $234 · 2023: $362 · 2024: $443 · 2025: $83.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $31.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.40 |
| Education | $31.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.33 | 2019 | |
| Travere Therapeutics, INC. | $151.38 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $121.88 | 2022-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $119.65 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $117.38 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $103.05 | 2022-2024 | Jynarque |
| Daiichi Sankyo INC. | $100.87 | 2021-2025 | Injectafer |
| Medtronic, INC. | $97.79 | 2021-2023 | Chameleon |
| Ani Pharmaceuticals, INC. | $51.73 | 2022-2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $51.11 | 2022-2023 | |
| Cormedix INC. | $45.90 | 2024 | Defencath |
| Ardelyx, INC. | $38.41 | 2024 | Ibsrela |
| Ucb, INC. | $35.79 | 2024 | Briviact |
| Fresenius USA Marketing, INC. | $34.42 | 2024 | Nxstage System One, Liberty Select Cycler |
| Novartis Pharmaceuticals Corporation | $32.26 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.44 | 2024 | Jardiance |
| Novo Nordisk INC | $29.93 | 2023 | Ozempic, Rybelsus |
| Ultragenyx Pharmaceutical INC. | $28.93 | 2023 | |
| Calliditas Therapeutics US INC. | $22.40 | 2023 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $21.06 | 2023 | Rayaldee |
| Amgen INC. | $17.17 | 2024 | Tavneos |
| Horizon Therapeutics Plc | $15.24 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Sherchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.